[低剂量重组干扰素α-2a治疗皮肤病期间干扰素抗体的产生]
[Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
作者信息
Corbillet V, Celerier P, Lebon P, Litoux P, Dreno B
机构信息
Clinique Dermatologique, CHU, Nantes.
出版信息
Ann Med Interne (Paris). 1995;146(6):399-403.
In this study, we determined the frequency of interferon antibodies in patients with skin diseases treated with low doses of recombinant interferon alpha 2a (1.5 - 18 x 10(6) IU). We assayed serum specimens from 181 patients with malignant melanoma or cutaneous T cell lymphomas (78 patients treated with recombinant interferon alpha 2a and 103 patients in control group) for interferon antibodies before treatment and every 6 months for at least 18 months. Neutralizing interferon alpha 2a antibodies were detected in 27 of 77 treated patients (35%), but none in control group (p < 10(-6)): 38.2% in melanoma and 12.5% in T cell lymphomas. However antibody formation was not correlated with nonresponse or with frequency of interferon antibodies in patients receiving the combined therapy: interleukin-2 and interferon alpha 2a.
在本研究中，我们测定了接受低剂量重组干扰素α2a（1.5 - 18×10⁶IU）治疗的皮肤病患者中干扰素抗体的出现频率。我们检测了181例恶性黑色素瘤或皮肤T细胞淋巴瘤患者（78例接受重组干扰素α2a治疗，103例为对照组）治疗前及之后至少18个月内每6个月的血清标本中的干扰素抗体。在77例接受治疗的患者中有27例（35%）检测到中和性干扰素α2a抗体，而对照组未检测到（p < 10⁻⁶）：黑色素瘤患者中为38.2%，T细胞淋巴瘤患者中为12.5%。然而，抗体形成与联合治疗（白细胞介素-2和干扰素α2a）患者的无反应情况或干扰素抗体频率无关。
Zotero 插件